Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.60 0.65% 1,647.20 1,644.60 1,645.20 1,653.60 1,620.80 1,627.20 10,986,803 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.5 82,872

GlaxoSmithKline Says Sotrovimab Antibody Retains Activity Against Omicron

02/12/2021 7:55am

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

From Nov 2021 to Jan 2022

Click Here for more Glaxosmithkline Charts.

By Joe Hoppe


GlaxoSmithKline PLC said Thursday that preclinical data shows its Sotrovimab antibody retains its effectiveness against key mutations found in the Omicron coronavirus variant.

The British pharmaceutical major said that the data was created through pseudo-virus testing of specific individual mutations found in the variant, and to date Sotrovimab has demonstrated persistent activity against all tested variants of concern and interest defined by the World Health Organization.

The company said it was now completing in vitro pseudo-virus testing to confirm Sotrovimab can neutralize a combination of all the Omicron mutations, and intends to provide an update by the end of 2021.

GlazoSmithKline said that the antibody was designed with Vir Biotechnology Inc. with a mutating virus in mind, and by targeting a highly conserved region of the spike protein that was less likely to mutate it hoped to address both the current coronavirus and future variants.

The antibody is authorized for emergency use in the U.S. and has received a positive opinion from E.U. bodies. It is also available in other global markets, including the U.K., Japan, Australia, Canada, Singapore and the United Arab Emirates.

"Though early, these pre-clinical data support our long-held view on the potential for Sotrovimab to maintain its activity as the virus continues to mutate," Chief Scientific Officer Hal Barron said.


Write to Joe Hoppe at joseph.hoppe@wsj.com


(END) Dow Jones Newswires

December 02, 2021 02:40 ET (07:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220121 21:28:54